Cytogenetic Abnormalities Do Not Affect Prognosis in Pediatric CML
Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia.
Gemcitabine Fails in Early Breast Cancer
Final 10-year follow-up of a large phase III trial showed that adding gemcitabine to anthracycline and taxane-based adjuvant chemotherapy increases toxicity and does not improve disease-free survival in early breast cancer patients.
Prostate Cancer Molecular Subtyping Groups Tumors by Prognosis, Response
Molecular subtyping of prostate cancer into three categories—luminal A, luminal B, and basal—identifies differences in prognosis and response to treatment.
Pembrolizumab Gets New Indications in Advanced Cancer
The FDA has granted approval to pembrolizumab (Keytruda) in the first- and second-line settings for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Oncologists Reluctant to Give Exercise Recommendations to Cancer Patients
Both oncologists and cancer patients recognize the benefits of physical activity during treatment, but oncologists may feel ill-equipped to give recommendations on exercise, according to a new study.
Single Surveillance Visit Reduced CRC Incidence in Adenoma Patients
Attending at least one surveillance visit with colonoscopy benefited most patients diagnosed with intermediate-risk adenomas, according to the results of a retrospective study.
Urinary RNA Testing Could Avoid Unnecessary Prostate Biopsies
Urinary testing for PCA3 and TMPRSS2:ERG (T2:ERG) RNA can help avoid unnecessary biopsies while maintaining ability to detect aggressive prostate cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.